Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, multi-dose study of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) in patients with acute myeloid leukaemia and myelodysplastic syndrome

Next Previous
X
Search
Trial Profile

A phase I, multi-dose study of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) in patients with acute myeloid leukaemia and myelodysplastic syndrome

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lintuzumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Seagen; Seattle Genetics

    • Most Recent Events

    • 24 Aug 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from active, no longer recruiting to completed, according to a Seattle Genetics media release.
    • 09 Jun 2009 Final results presented at the 14th Congress of the European Hematology Association (EHA), according to a Seattle Genetics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top